Skip to main content

Table 1 Characteristics of included studies

From: Adjuvant therapy for retroperitoneal sarcoma: a meta-analysis

Study (author, year) Patient source Type of study Number of patients (treat/control) Age (years) High malignancy grade Tumour size (cm) Intervention (treat/control) Surgical margins Radiotherapy/chemotherapy Outcome HR (95%CI) NOS score
Treat Control Treat (%) Control (%) Treat Control Treat (Neg/Pos) Control (Neg/Pos) Dose (Gy)/ Drug
Adjuvant radiotherapy
 Nussbaum et al. 2016a (19) USA RCS 2196/2196 59.5(13.9) # 59.4(15.3) # 63 62 12.8(12) # 12.9(11.5) Sur + RT/Sur 1338/858 1377/819 50(45–54) OS 0.78 (0.71–0.85) 8
 Trovik et al. 2014(8) Norway RCS 42/55 61(35–82) § 63(15–83) § 34 37 19(6–60) § 19(4–43) § Sur + RT/Sur 25/17 29/26  < 50 OS 0.36 (0.18–0.72) 8
MFS 0.42 (0.20–0.88)
LR 0.20 (0.09–0.45)
 Bates et al. 2018(10) USA RCS 144/336 Sur + RT/Sur OS 0.42 (0.19–0.90) 7
Zhou et al. 2010(13) USA RCS 364/1183 Sur + RT/Sur OS 0.78 (0.63–0.95) 7
 Lepechoux et al. 2013(12) France RCS 56/42 50(21–80) § 54(19–77) § 40 24 15(6–46) § 20(4–60) § Sur + RT/Sur 50.4(14–62) § OS 0.91 (0.34–1.39) 8
               RFS 0.43 (0.20–0.88)  
 Chouliaras et al. 2019a (21) USA RCS 59/59 58.2(52–70) 65.8(52–77) 74.6 71.2 12.5(8.5–20) 15(8–23) Sur + RT/Sur 34/25 32/27 50.4(45, 54.3) OS 0.80 (0.47–1.35) 8
               RFS 0.70 (0.43–1.14)  
               LR 0.47 (0.21–1.06)  
 Miura et al. 2015a† (18) USA RCS 938/3050 \(\le 10\)(26.8%) \(\le 10\)(27.7%) Sur + RT/Sur OS 0.79 (0.70–0.90) 8
         10–20(34.5%) 10–20(35.0%)        
         \(\ge 20\)(17.7%) \(\ge 20\)(18.8%)        
Gronchi et al. 2012† (17) Italy RCS 101/230 57(48–67) 35 17(10–26) Sur + RT/Sur Neg/Pos: 305/26 50(36–65) § OS 0.64 (0.41–1.00) 7
               RFS 0.57 (0.35–0.92)  
               MFS 2.38 (1.34–4.42)  
Gronchi et al. 2009† (16) Italy RCS 88/200 55(47–66) 35.8 16(10–26) Sur + RT/Sur Neg/Pos: 257/31 50 (36–65) § OS 0.55 (0.35–0.86) 7
               RFS 0.65 (0.42–1.01)  
               MFS 1.47 (0.81–2.68)  
Stahl et al. 2017† (15) USA RCS 1132/2772 60§ 52.2 16(0.3–90) § Sur + RT/Sur Neg/Pos: 2593/1422 50.4(45–54.1) OS 0.81 (0.70–0.93) 8
Tseng et al. 2011(9) USA RCS 373/1130 61.5(14.8) # 31.8 15.5(0.5–99.5) § Sur + RT/Sur Neg/Pos: 660/875 OS 0.92 (0.78–1.09) 7
Klooster et al. 2016† (20) USA RCS 102/293 63(53–72) 49 20(12–44) Sur + RT/Sur Neg/Pos: 0/395 OS 0.78 (0.58–1.05) 7
Berger et al. 2018(22) USA RCS 550/2212 62.9(11.2) # 39.1 19.9(11.9) # Sur + RT/Sur Neg/Pos: 1445/1317 OS 0.80 (0.68–0.94) 7
Nathan et al. 2009(5) USA RCS 254/1365 63§ 37 17(0.5–99) § Sur + (RT + IORT)/Sur OS 0.95 (0.78–1.15) 7
Adjuvant chemotherapy
 Datta et al. 2017(11) USA RCS 390/377 \(\le 62\)(72.3%) 63–71(20.0%) \(\ge 72\)(7.7%) \(\le 62\)(67.1%) 63–71(24.1%) \(\ge 72\)(8.8%) 77.2 78 \(\le 10\)(24.4%) 10–20(48.5%) \(\ge 20\)(27.1%) \(\le 10\)(23.3%) 10–20(47.6%) \(\ge 20\)(29.1%) Sur + CT/Sur 180/210 170/207 OS 1.30 (1.05–1.61) 8
 Miura et al. 2015a‡ (18) USA RCS 1525/1525 55(43–64) 57(48–64) 30.2 29.8 \(\le 10\)(26.8%) 10–20(34.5%) \(\ge 20\)(17.7%) \(\le 10\)(27.7%) 10–20(35.0%) \(\ge 20\)(18.8%) Sur + CT/Sur 614/911 629/896 OS 1.17 (1.04–1.31) 8
 Klooster et al. 2016‡ (20) USA RCS 122/273 63(53–72) 49 20(12–44) Sur + CT/Sur Neg/Pos: 0/395 OS 1.09 (0.83–1.45) 8
 Gronchi et al. 2009‡ (16) Italy RCS 182/394 55(47–66) 35.8 16(10–26) Sur + CT/Sur Neg/Pos: 257/31 OS 1.30 (0.86–1.97) 7
               RFS 1.34 (0.88–2.05)  
               MFS 0.72 (0.39–1.24)  
 Gronchi et al. 2012‡ (17) Italy RCS 218/444 57(48–67) 35 17(10–26) Sur + CT/Sur Neg/Pos: 305/26 OS 1.14 (0.74–1.75) 7
               RFS 1.26 (0.80–1.97)  
               MFS 0.66 (0.36–1.20)  
 Stahl et al. 2017‡ (15) USA RCS 445/3447 60§ 52.2 16(0.3–90) § Sur + CT/Sur Neg/Pos: 2593/1422 OS 0.82 (0.67–0.99) 8
  1. CI, confidence interval; DSS, disease-specific survival; HR, hazard ratio; LR, local recurrence; Neg, negative; OS, overall survival; Pos, positive; RCS, retrospective cohort study; RCT, randomized clinical trial; RFS, recurrence-free survival; RT, radiotherapy, Sur, Surgery
  2. aPropensity score matched (PSM); †,‡Adjuvant radiotherapy (†) and adjuvant chemotherapy (‡) in the same study; # Data are mean (SD); § Data are median or median (range); Data are median (IQR)